Autolus Therapeutics’ Post

Did you know that 72% of healthcare professionals are concerned about the credibility of Digital Therapeutics (DTx)? However, DTx can vastly improve patient outcomes and engagement. Find out how to overcome the challenges in our latest report on digital therapeutics. https://bit.ly/3wYtHKT #DTx #digitalhealthcare #IQVIA

Did you know that DTx has positive benefits for patient outcomes and engagement? Check the latest report below.

Agreed, the patient-centric approach is so important when it comes to treatments.

Arwen Podesta, MD, ABPN, FASAM, ABIHM, highlights key factors for successful implementation of the use prescription digital therapeutics (PDTs) in clinical settings, discussing how patient care and outcomes are impacted. Watch the K-Cast series to learn more: [link] #ManagedCare #MentalHealthCare #PDT

In this K-Cast episode, Diana Brixner, discusses the level of clinical evidence payers should expect and require from non-prescription digital health tools compared to FDA-approved digital therapeutics! Brixner offers insight as to where the biggest gaps in evidence generation for digital therapeutics come from. Watch here: https://bit.ly/4drOvLE #ManagedCare #DigitalHealth

Integrated 🩺 healthcare is a patient-centered approach that involves a collaborative and coordinated effort from a multidisciplinary team of healthcare professionals. By offering in-office 🧪 biologics, rheumatologists can begin providing more integrated patient care, improving health outcomes, treatment adherence, and more.

In a recent CRA webinar on evolving business models for DTx (Digital Therapeutics) Rhett Johnson and Andy Parece discussed with a panel of industry leaders, Richard DeNunzio, Omar Manejwala, M.D., and Brion Raymond, how events in the past year, from introduction of new HSPCS billing codes to Pear Therapeutics’ bankruptcy and the transition of some DTx manufacturers to alternative business models, impact their companies. Each panelist discussed business models their company is employing, including prescription digital therapeutics, collaboration with employers to fund solutions and with pharma companies to collaborate partner in research and commercialization. The discussion covered the drivers behind the choice of each business model as well as their advantages, and showed how they are related to the specific product, indication and available clinical evidence base. To learn more and watch the webinar recording, click here: https://lnkd.in/gjdbCBTd #DigitalTherapeutics

Digital therapeutics: policy, access, value, and evidence https://lnkd.in/g6WB3Pq6 Digital therapeutics are quickly becoming one of the fastest-growing fields in healthcare. Innovation by regulators, policy-makers, and payers is needed to ensure that patients can access and benefit from these technologies. Successful market access is key to delivering individual patient benefits, potential healthcare system gains, and a meaningful integration of digital therapeutics into our healthcare infrastructure at a population level. Download this free report, which examines key aspects of policy, access, value, and evidence for digital therapeutics. https://lnkd.in/g6WB3Pq6 #MarketAccess #HEOR #WeAreAvalereHealth

As digital therapeutics becomes more and more mainstream, its important to understand how the pathways for its reimbursement are evolving across international markets and what are the access challenges that lie ahead. Here is a report that helps frame the challenges succinctly and examines the key aspects of policy, access, value and evidence from a global as well as APAC lens. Feel free reach out for more information!

What steps will you take to ensure your new, innovative radiopharmaceutical delivers on its clinical promise and achieves successful commercial adoption? We've got some suggestions. Tune in to Fractals: Life Science Conversations with guest Andrew Beck to unravel the mysteries of the radiopharmaceutical 'unk-unk', understand the significance of patient education in sales, and learn why an integrated approach is pivotal for effective strategy. https://lnkd.in/gspsAYfq #Radiopharmaceuticals #CommercializationStrategy #LifeSci #Bracken